TD Asset Management Inc. bought a new stake in Fresenius Medical Care Corporation (NYSE:FMS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,108 shares of the company’s stock, valued at approximately $641,000.
A number of other institutional investors also recently modified their holdings of the business. D.A. Davidson & CO. boosted its position in Fresenius Medical Care by 6.8% in the third quarter. D.A. Davidson & CO. now owns 16,854 shares of the company’s stock valued at $823,000 after buying an additional 1,077 shares in the last quarter. Pacer Advisors Inc. boosted its position in Fresenius Medical Care by 37.6% in the third quarter. Pacer Advisors Inc. now owns 5,105 shares of the company’s stock valued at $250,000 after buying an additional 1,394 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Fresenius Medical Care in the third quarter valued at approximately $527,000. Fragasso Group Inc. boosted its position in Fresenius Medical Care by 11.4% in the third quarter. Fragasso Group Inc. now owns 23,139 shares of the company’s stock valued at $1,131,000 after buying an additional 2,375 shares in the last quarter. Finally, Comerica Bank boosted its position in Fresenius Medical Care by 4.1% in the third quarter. Comerica Bank now owns 47,848 shares of the company’s stock valued at $2,317,000 after buying an additional 1,876 shares in the last quarter. Hedge funds and other institutional investors own 3.03% of the company’s stock.
A number of analysts have weighed in on FMS shares. Zacks Investment Research upgraded shares of Fresenius Medical Care from a “sell” rating to a “hold” rating and set a $53.00 target price on the stock in a research report on Monday, October 9th. DZ Bank reiterated a “buy” rating on shares of Fresenius Medical Care in a report on Monday, November 13th. Royal Bank of Canada reiterated a “hold” rating and set a $44.00 price target on shares of Fresenius Medical Care in a report on Wednesday, September 13th. Finally, Morgan Stanley lowered shares of Fresenius Medical Care from an “overweight” rating to an “equal weight” rating in a report on Monday. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $48.50.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/12/15/13108-shares-in-fresenius-medical-care-corporation-fms-purchased-by-td-asset-management-inc.html.
About Fresenius Medical Care
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.